CN115671022B - Anti-aging microcapsule composition and preparation method and application thereof - Google Patents
Anti-aging microcapsule composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN115671022B CN115671022B CN202211392364.XA CN202211392364A CN115671022B CN 115671022 B CN115671022 B CN 115671022B CN 202211392364 A CN202211392364 A CN 202211392364A CN 115671022 B CN115671022 B CN 115671022B
- Authority
- CN
- China
- Prior art keywords
- microcapsule composition
- aging
- isopropyl myristate
- fibronectin
- soybean lecithin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 239000003094 microcapsule Substances 0.000 title claims abstract description 41
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 29
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 28
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 25
- 229940083466 soybean lecithin Drugs 0.000 claims description 25
- 102000016359 Fibronectins Human genes 0.000 claims description 23
- 108010067306 Fibronectins Proteins 0.000 claims description 23
- 241000881711 Acipenser sturio Species 0.000 claims description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 17
- 239000006185 dispersion Substances 0.000 claims description 17
- 239000011159 matrix material Substances 0.000 claims description 17
- 229960000735 docosanol Drugs 0.000 claims description 14
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 12
- 239000004519 grease Substances 0.000 claims description 12
- OBETXYAYXDNJHR-UHFFFAOYSA-N 2-Ethylhexanoic acid Chemical compound CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims description 10
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 claims description 10
- 150000002632 lipids Chemical class 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 8
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 6
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 6
- 229960001631 carbomer Drugs 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000011324 bead Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 238000005562 fading Methods 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 40
- 239000004480 active ingredient Substances 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 210000003491 skin Anatomy 0.000 description 17
- 102000016387 Pancreatic elastase Human genes 0.000 description 12
- 108010067372 Pancreatic elastase Proteins 0.000 description 12
- 230000037303 wrinkles Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000013543 active substance Substances 0.000 description 7
- 230000032683 aging Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 235000015067 sauces Nutrition 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- -1 ethyl caproic acid Chemical compound 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000037384 skin absorption Effects 0.000 description 2
- 231100000274 skin absorption Toxicity 0.000 description 2
- 230000036620 skin dryness Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- JNYGZAJRVPTELQ-UHFFFAOYSA-N 2-ethylhexanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCC(CC)C(O)=O.CCCCC(CC)C(O)=O.CCCCC(CC)C(O)=O JNYGZAJRVPTELQ-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an anti-aging microcapsule composition and a preparation method and application thereof. The anti-aging microcapsule composition provided by the invention has the advantages of anti-aging effect, fine lines fading, easiness in application and pushing away, and better use feeling.
Description
Technical Field
The invention relates to the technical field of cosmetics, in particular to an anti-aging microcapsule composition, a preparation method and application thereof.
Background
The functional components in cosmetics are very important and are the main components for the effectiveness of cosmetics. In order to maximize the activity of the functional ingredient, on the one hand, protection by the dosage form may be provided during the manufacture of the product. For example, the active ingredient is encapsulated in liposome, microcapsule, etc. to prevent oxidation of the active ingredient. On the other hand, skin absorption of the active ingredient can be promoted by optimizing the formulation. If the active ingredient is protected against oxidation before the product is used, the absorption of the active ingredient can be improved during use, so that the active ingredient can be maximally utilized.
Applicant discloses in patent CN2022108313047 a microcapsule encapsulating an active, from the point of view of protecting the active ingredient before use of the product. The patent has not been developed from the practical point of view in connection with the actual application of the active ingredient, and has not considered the problems of the absorbability and the feeling of use of the active ingredient.
Disclosure of Invention
In order to overcome the defects of the prior art, one of the purposes of the invention is to provide an anti-aging microcapsule composition which can resist aging, lighten fine lines, is easy to paint and push away, and has better use feeling.
The second purpose of the invention is to provide a preparation method of the anti-aging microcapsule composition.
The invention further aims at providing an application of the anti-aging microcapsule composition.
One of the purposes of the invention is realized by adopting the following technical scheme:
an anti-aging microcapsule composition comprising oil droplets and a dispersion matrix, the oil droplets being uniformly suspended in the dispersion matrix, the oil droplets comprising an active comprising sturgeon caviar extract and fibronectin, and a lipid component comprising tri (ethylhexanoate), behenyl alcohol and a synthetic wax.
As a preferred embodiment of the present invention, the lipid component further comprises soybean lecithin and isopropyl myristate. The soybean lecithin and isopropyl myristate both have surface activity and good lipophilicity, can permeate into intercellular lipid of horny layer, influence the compactness and fluidity of lipid bilayer arrangement, and promote the skin to absorb sturgeon roe sauce extract and fibronectin. In addition, the soybean lecithin can repair damaged cell membranes, increase the unsaturated degree of fatty acid in the cell membranes, improve the regeneration capacity of organism tissues and delay the aging of human bodies. The isopropyl myristate also has the function of moisturizing, and can moisten skin, improve skin dryness and enable the skin to be smooth and fine.
The sturgeon caviar extract and fibronectin are used as active substances, and soybean lecithin, isopropyl myristate, triglyceride (ethyl caproic acid) ester, behenyl alcohol and synthetic wax are used as grease components, so that the efficacy of the active substances can be well protected, the active substances can be promoted to permeate into skin and promote absorption, and the compatibility of the grease components is good, the grease components are not easy to separate out after being prepared into oil drops, and the stability is good; meanwhile, the oil drop has good spreadability, no stickiness and good skin friendliness.
As a preferred embodiment of the present invention, the actives comprise, in weight percent in the microcapsule composition: 2-5% of sturgeon caviar extract and 0.005-0.02% of fibronectin.
As a preferred embodiment of the present invention, the lipid component comprises, in weight percent in the microcapsule composition: 0.5 to 1.5 percent of soybean lecithin, 1 to 8 percent of isopropyl myristate, 20 to 25 percent of triglyceride (ethylhexanoic acid) ester, 3 to 5 percent of behenyl alcohol and 0.5 to 1.5 percent of synthetic wax.
As a preferred embodiment of the present invention, the actives comprise, in weight percent in the microcapsule composition: 2.5-4.5% of sturgeon caviar extract and 0.01-0.015% of fibronectin; the grease component comprises: 0.8-1.2% of soybean lecithin, 3-5% of isopropyl myristate, 21-24% of triglyceride (ethylhexanoic acid) ester, 3.5-4.5% of behenyl alcohol and 0.8-1.2% of synthetic wax.
As a preferred embodiment of the present invention, the actives comprise, in weight percent in the microcapsule composition: 3% of sturgeon caviar extract and 0.01% of fibronectin; the grease component comprises: soybean lecithin 1%, isopropyl myristate 5%, glyceryl tri (ethylhexanoate) 21%, behenyl alcohol 4% and synthetic wax 1%.
As a preferred embodiment of the present invention, the dispersion matrix comprises, in terms of weight percentage in the microcapsule composition, 8 to 15% of glycerin, 0.3 to 0.8% of 1, 2-hexanediol, 0.3 to 0.8% of p-hydroxyacetophenone, 0.1 to 0.2% of carbomer, 0.1 to 0.2% of triethanolamine, 0.01 to 0.05% of EDTA disodium, and 55 to 65% of water.
As a preferred aspect of the present invention, an anti-aging microcapsule composition comprising oil droplets and a dispersion matrix, the oil droplets being uniformly suspended in the dispersion matrix, the oil droplets comprising an active and a lipid component; the actives include, in weight percent in the microcapsule composition: 2-5% of sturgeon caviar extract and 0.005-0.02% of fibronectin; the grease component comprises: 0.5-1.5% of soybean lecithin, 1-8% of isopropyl myristate, 20-25% of triglyceride (ethylhexanoic acid) ester, 3-5% of behenyl alcohol and 0.5-1.5% of synthetic wax; the dispersion matrix comprises 8-15% of glycerin, 0.3-0.8% of 1, 2-hexanediol, 0.3-0.8% of p-hydroxyacetophenone, 0.1-0.2% of carbomer, 0.1-0.2% of triethanolamine, 0.01-0.05% of EDTA disodium and 55-65% of water.
The second purpose of the invention is realized by adopting the following technical scheme:
a method of preparing an anti-aging microcapsule composition comprising the steps of:
mixing soybean lecithin, isopropyl myristate, glycerol tri (ethylhexanoate), behenyl alcohol and synthetic wax, heating to 70-90 ℃, thoroughly dissolving, adding sturgeon caviar extract and fibronectin, uniformly dissolving to obtain a mixture, and preserving heat for later use;
adding the mixture into a granulator for granulating, cooling to room temperature after forming, and obtaining oil beads;
sequentially adding glycerol, 1, 2-hexanediol, p-hydroxyacetophenone, carbomer, triethanolamine and EDTA disodium into water, heating and mixing uniformly to obtain a dispersion matrix, and cooling to room temperature;
uniformly suspending the oil droplets in the dispersion matrix to obtain the anti-aging microcapsule composition.
The third purpose of the invention is realized by adopting the following technical scheme:
the invention also provides application of the anti-aging microcapsule composition in preparing cosmetics.
The invention also provides the application of the microcapsule composition prepared by the preparation method in preparing cosmetics.
As a preferred embodiment of the present invention, the cosmetic includes a cleansing cream, a toner, an emulsion, an essence, a cream, and a lotion.
Compared with the prior art, the invention has the beneficial effects that:
(1) According to the microcapsule composition provided by the invention, the active ingredients are wrapped in the grease component to form the oil globules integrally, so that the oxidation of the active ingredients can be effectively avoided, a good protection effect is achieved, and the effectiveness of the active ingredients is maximized.
(2) The microcapsule composition provided by the invention comprises fibronectin and sturgeon caviar extract as active ingredients. Wherein, fibronectin can promote cell adhesion, regulate cell growth, regulate skin immunity, and play roles in multidimensional repair and anti-aging; in addition, the fibronectin can accelerate metabolism of skin cells, quickly discharge skin metabolic wastes, repair vascular endothelial cells, recover elasticity of peripheral blood vessels, improve skin microcirculation, promote normal and orderly operation of the skin microcirculation system, and ensure that the skin is always in a dry, healthy and transparent state.
(3) The microcapsule composition provided by the invention has the advantages that the sturgeon roe sauce extract can effectively inhibit the activity of elastase, slow down the degradation speed of elastin, and play roles in delaying aging and reducing wrinkles. Can also improve skin hydration, barrier function and wound healing ability, promote KC proliferation, migration and differentiation, and play an anti-aging role.
Drawings
Fig. 1 is a graph showing the wrinkle-removing effect of the volunteer of example 1 of the present invention.
Detailed Description
The present invention will be further described with reference to the following specific embodiments, and it should be noted that, on the premise of no conflict, new embodiments may be formed by any combination of the embodiments or technical features described below. The raw materials, equipment and the like used in the examples described below are commercially available except for special restrictions.
Examples 1 to 3 and comparative examples 1 to 6
An anti-aging microcapsule composition comprises oil droplets and a dispersion matrix, wherein the oil droplets are uniformly suspended in the dispersion matrix, and the oil droplets comprise an active substance and a lipid component. The specific composition is shown in Table 1.
Table 1 (weight percent/%)
The anti-aging microcapsule compositions of examples 1-3 and comparative examples 1-6 were prepared as follows:
1. mixing the oil components according to the formula amount, heating to 85 ℃, thoroughly dissolving, adding sturgeon caviar extract and/or fibronectin, dissolving uniformly to obtain a mixture, and preserving heat for later use;
2. adding the mixture obtained in the step 1 into a granulator for granulation, cooling to room temperature after forming, and obtaining oil droplets;
3. sequentially adding glycerol, 1, 2-hexanediol, p-hydroxyacetophenone, carbomer, triethanolamine and EDTA disodium into water, heating and mixing uniformly to obtain a dispersion matrix, and cooling to room temperature;
4. uniformly suspending the oil droplets obtained in the step 2 in the dispersion matrix obtained in the step 3 to obtain the anti-aging microcapsule composition.
Effect verification
1. Wrinkle removal test
135 female volunteers with healthy facial skin were selected, with ages ranging from 35 to 45, and equally divided into 9 groups of 15 persons each, each group of volunteers tested the anti-aging microcapsule compositions of examples 1-3 and comparative examples 1-6, respectively. The medicine is applied to the region of the canthus fish tail vein, the dosage is 3ml each time, and the medicine is applied for 28 days in the morning and evening. The reduction of fish tail wrinkles (fine lines) was evaluated using the facial imaging system visual-CR, and the results are shown in table 2, each as an average of the 15 volunteers of the group.
In addition, each volunteer scored the test samples from mild skin-friendly, moisturized, oil-droplet soluble, push-open spreadability, absorbency, from 0-10 points, with higher scores, and average values for the group of 15 volunteers for each result, as shown in table 3.
TABLE 2 Table of results of wrinkle removal for samples of examples 1-3 and comparative examples 1-6
Examples 1-3 use fibronectin and sturgeon roe paste extract as active substances and soy lecithin, isopropyl myristate, tri (ethylhexanoate) glycerol, behenyl alcohol and synthetic wax as lipid ingredients, which can well protect the efficacy of the active substances, promote penetration of the active substances into the skin and promote absorption. The soybean lecithin and isopropyl myristate both have surface activity and good lipophilicity, can permeate into intercellular lipid of horny layer, influence the compactness and fluidity of lipid bilayer arrangement, and promote the skin to absorb sturgeon roe sauce extract and fibronectin. In addition, the soybean lecithin can repair damaged cell membranes, increase the unsaturated degree of fatty acid in the cell membranes, improve the regeneration capacity of organism tissues and delay the aging of human bodies. The isopropyl myristate also has the function of moisturizing, and can moisten skin, improve skin dryness and enable the skin to be smooth and fine. The anti-aging microcapsule compositions of examples 1-3 all achieved a good wrinkle-removing effect.
The oil and fat component of comparative example 1 contains less soybean lecithin and isopropyl myristate, the dosage of triglyceride (ethyl caproic acid), behenyl alcohol and synthetic wax is adjusted, the penetration enhancer of comparative example 1 contains less, and the wrinkle removing effect of the sample is greatly reduced. The active ingredient of comparative example 2 was less sturgeon caviar extract, the active ingredient of comparative example 3 was less fibronectin, and it was found from the table that the wrinkle-removing effects of comparative examples 2 to 3 were all reduced to different extents. The oil and fat component of comparative example 4 was reduced to soybean lecithin, and the amount of isopropyl myristate was adjusted to 6%; the oil and fat component of comparative example 5 was reduced to isopropyl myristate, and the amount of soybean lecithin was adjusted to 6%. Although the total amount of the permeation enhancer was not changed in comparative examples 4 to 5, one of them was absent, resulting in a decrease in the wrinkle-removing effect. Comparative example 6 replacement of isopropyl myristate with isopropyl palmitate also resulted in poor wrinkle-removing effect. Therefore, each component in the oil and fat comprises fibronectin and sturgeon roe sauce extract in the active component, and soybean lecithin and isopropyl myristate in the oil and fat components can have a great influence on the wrinkle removing effect, and the components are matched with each other to jointly promote the wrinkle removing effect.
As shown in FIG. 1, the effect of one of volunteers using the sample of example 1 of the present invention was shown to be remarkable in wrinkle removal after 4 weeks of use.
The embodiment of the invention combines proper active ingredients and grease ingredients, so that the wrinkle removing effect is optimal.
Table 3 volunteer use evaluation chart
| Mild skin-friendly degree | Moisture and preserve moisture | Solubility of oil globules | Push-open spreadability | Absorbency of | |
| Example 1 | 9.3 | 9.5 | 8.6 | 8.8 | 8.6 |
| Example 2 | 9.2 | 9.1 | 8.4 | 8.3 | 8.2 |
| Example 3 | 9.0 | 9.3 | 8.6 | 8.2 | 8.4 |
| Comparative example 1 | 8.8 | 7.5 | 6.9 | 6.5 | 5.9 |
| Comparative example 2 | 9.1 | 8.2 | 8.0 | 7.9 | 7.5 |
| Comparative example 3 | 8.9 | 8.6 | 8.1 | 7.8 | 7.3 |
| Comparative example 4 | 8.5 | 8.0 | 7.8 | 7.5 | 6.8 |
| Comparative example5 | 8.9 | 8.3 | 7.4 | 7.1 | 6.6 |
| Comparative example 6 | 8.2 | 8.3 | 7.1 | 7.3 | 6.3 |
As can be seen from the records in table 3, the samples of examples 1-3 all have higher scores in each index, resulting in a higher use rating. Whereas the active ingredient of comparative example 2 was less sturgeon caviar extract and the active ingredient of comparative example 3 was less fibronectin, their evaluation in each index was reduced to a different extent. The oil and fat component of comparative example 1 lacks soybean lecithin and isopropyl myristate, the oil and fat component of comparative example 4 lacks soybean lecithin, the oil and fat component of comparative example 5 lacks isopropyl myristate, and comparative example 6 replaces isopropyl myristate with isopropyl palmitate, which have a great influence on the solubility, push-away spreadability and absorbability of the oil droplets, resulting in a reduced sense of use experience.
2. Elastase inhibition assay
To the test system (120. Mu.L, 20mmol/L Tris-HCl buffer solution, pH=8.0), 20. Mu.L elastase solution (dissolved by Tris-HCl buffer solution) was added, 10. Mu.L of the test solution (stock solutions formed by dissolving the anti-aging microcapsule compositions of examples 1 to 3 and comparative examples 1 to 6 respectively in DMSO, diluted to a concentration of 125. Mu.g/mL at the time of the test) was added, and finally 50. Mu.L of substrate N-succinyl-Ala-Ala-Ala-p-nitroaniline solution was added to the test system, mixed uniformly, and the absorbance at a wavelength of 410nm was measured using an enzyme-labeled instrument. In addition, 10. Mu.L of TrisHCL buffer solution was added as a blank instead of the test solution, and used as a control group. The results are shown in Table 4 below.
Table 4 elastase inhibition test
| Elastase inhibition rate | |
| Example 1 | 48.89％ |
| Example 2 | 47.29％ |
| Example 3 | 47.45％ |
| Comparative example 1 | 40.18％ |
| Comparative example 2 | 36.15％ |
| Comparative example 3 | 29.37％ |
| Comparative example 4 | 42.21％ |
| Comparative example 5 | 43.16％ |
| Comparative example 6 | 42.29％ |
| Blank group | 0％ |
The activity of elastase treated in the blank group was set to 100%, i.e., the blank group had no inhibitory effect on elastase activity, and the inhibition ratio was 0.
The results in Table 3 show that the samples of examples 1-3 have a high elastase inhibition rate of 47% or more. The active ingredient of comparative example 2 was less sturgeon caviar extract, the active ingredient of comparative example 3 was less fibronectin, and it was found from the table that the elastase of comparative examples 2-3 showed a large decrease. The fibronectin and sturgeon caviar extract are used together as active ingredients, the inhibition rate of elastase is greatly increased, a synergistic effect is achieved, and the effect is far beyond the simple superposition effect.
The oil and fat component with less content in comparative example 1 contains less soybean lecithin and isopropyl myristate, and the dosage of triglyceride (ethyl caproic acid), behenyl alcohol and synthetic wax is adjusted; the oil and fat component of comparative example 4 was reduced to soybean lecithin, and the amount of isopropyl myristate was adjusted to 6%; the oil and fat component of comparative example 5 was reduced to isopropyl myristate, and the amount of soybean lecithin was adjusted to 6%; comparative example 6 isopropyl myristate was replaced with isopropyl palmitate. The results were unexpected in that the elastase inhibition rates of these comparative examples were reduced to varying degrees. Because the oil and fat components comprise soybean lecithin and isopropyl myristate, the oil and fat components mainly play a role in helping skin absorb active components, the efficacy of the active components is not affected by the oil and fat components, and the test system is a non-skin absorption test system, but the results show that the change of the oil and fat components also has a certain influence on the inhibition rate of elastase, and the results of the wrinkle removal test system are combined, so that the embodiment of the invention adopts the combination of the proper active components and the grease components, achieves a synergistic effect, can resist aging, remove wrinkles and keep the skin young and alive.
The above embodiments are only preferred embodiments of the present invention, and the scope of the present invention is not limited thereto, but any insubstantial changes and substitutions made by those skilled in the art on the basis of the present invention are intended to be within the scope of the present invention as claimed.
Claims (6)
1. An anti-aging microcapsule composition comprising oil droplets and a dispersion matrix, the oil droplets being uniformly suspended in the dispersion matrix, the oil droplets comprising an active and a lipid component;
the actives include, in weight percent in the microcapsule composition: 2-5% of sturgeon caviar extract and 0.005-0.02% of fibronectin; the grease component comprises: 0.5-1.5% of soybean lecithin, 1-8% of isopropyl myristate, 20-25% of triglyceride (ethylhexanoic acid) ester, 3-5% of behenyl alcohol and 0.5-1.5% of synthetic wax; the dispersion matrix comprises 8-15% of glycerin, 0.3-0.8% of 1, 2-hexanediol, 0.3-0.8% of p-hydroxyacetophenone, 0.1-0.2% of carbomer, 0.1-0.2% of triethanolamine, 0.01-0.05% of EDTA disodium and 55-65% of water.
2. The anti-aging microcapsule composition of claim 1, wherein the actives comprise, in weight percent in the microcapsule composition: 2.5-4.5% of sturgeon caviar extract and 0.01-0.015% of fibronectin; the grease component comprises: 0.8-1.2% of soybean lecithin, 3-5% of isopropyl myristate, 21-24% of triglyceride (ethylhexanoic acid) ester, 3.5-4.5% of behenyl alcohol and 0.8-1.2% of synthetic wax.
3. The anti-aging microcapsule composition of claim 1, wherein the actives comprise, in weight percent in the microcapsule composition: 3% of sturgeon caviar extract and 0.01% of fibronectin; the grease component comprises: soybean lecithin 1%, isopropyl myristate 5%, glyceryl tri (ethylhexanoate) 21%, behenyl alcohol 4% and synthetic wax 1%.
4. A method of preparing the anti-aging microcapsule composition of claim 1, comprising the steps of:
mixing soybean lecithin, isopropyl myristate, glycerol tri (ethylhexanoate), behenyl alcohol and synthetic wax, heating to 70-90 ℃, thoroughly dissolving, adding sturgeon caviar extract and fibronectin, uniformly dissolving to obtain a mixture, and preserving heat for later use;
adding the mixture into a granulator for granulating, cooling to room temperature after forming, and obtaining oil beads;
sequentially adding glycerol, 1, 2-hexanediol, p-hydroxyacetophenone, carbomer, triethanolamine and EDTA disodium into water, heating and mixing uniformly to obtain a dispersion matrix, and cooling to room temperature;
uniformly suspending the oil droplets in the dispersion matrix to obtain the anti-aging microcapsule composition.
5. Use of the anti-aging microcapsule composition of any of claims 1-3 or the microcapsule composition prepared by the preparation method of claim 4 in the preparation of cosmetics.
6. The use according to claim 5, wherein the cosmetic comprises a face lotion, a toner, an emulsion, an essence, a cream and a lotion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211392364.XA CN115671022B (en) | 2022-11-08 | 2022-11-08 | Anti-aging microcapsule composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211392364.XA CN115671022B (en) | 2022-11-08 | 2022-11-08 | Anti-aging microcapsule composition and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115671022A CN115671022A (en) | 2023-02-03 |
| CN115671022B true CN115671022B (en) | 2024-03-29 |
Family
ID=85049598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211392364.XA Active CN115671022B (en) | 2022-11-08 | 2022-11-08 | Anti-aging microcapsule composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115671022B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015033668A (en) * | 2013-08-08 | 2015-02-19 | サッポロビール株式会社 | Microcapsule, manufacturing method of microcapsule, and beverage/food |
| CN109674731A (en) * | 2019-02-14 | 2019-04-26 | 厦门汇聚优品电子商务有限公司 | A kind of anti-apolexis composition containing roe essence and its application |
| CN113712842A (en) * | 2020-05-25 | 2021-11-30 | 基元美业生物科技(上海)有限公司 | Composition and application thereof in preparation of cosmetics and medical instruments |
| CN115177536A (en) * | 2022-07-14 | 2022-10-14 | 广东丸物科技有限公司 | Microcapsule for wrapping active substances and preparation method thereof |
-
2022
- 2022-11-08 CN CN202211392364.XA patent/CN115671022B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015033668A (en) * | 2013-08-08 | 2015-02-19 | サッポロビール株式会社 | Microcapsule, manufacturing method of microcapsule, and beverage/food |
| CN109674731A (en) * | 2019-02-14 | 2019-04-26 | 厦门汇聚优品电子商务有限公司 | A kind of anti-apolexis composition containing roe essence and its application |
| CN113712842A (en) * | 2020-05-25 | 2021-11-30 | 基元美业生物科技(上海)有限公司 | Composition and application thereof in preparation of cosmetics and medical instruments |
| CN115177536A (en) * | 2022-07-14 | 2022-10-14 | 广东丸物科技有限公司 | Microcapsule for wrapping active substances and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115671022A (en) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108904302A (en) | A kind of fullerene topical composition | |
| KR101972071B1 (en) | Cosmetic composition for improving skin tone or skin elasticity | |
| CN106309154A (en) | Skin care substrate with long acting moisturizing and whitening effects and preparation and application of skin care substrate | |
| WO2008139182A2 (en) | Skin care composition | |
| KR20180138399A (en) | Inhibitor for NO activator, Anit-inflammation agent containing of the same, Revitalizing cosmetics containing the same and Manufacturing method thereof | |
| CN109846740B (en) | Skin care composition and preparation method and application thereof | |
| US7655255B2 (en) | Topical composition for transdermal administration | |
| CN112006958A (en) | Depilatory cream and preparation method thereof | |
| CN112641692A (en) | Anti-allergy repairing composition and preparation method and application thereof | |
| CN111514058A (en) | Skin whitening and brightening agent and preparation method thereof | |
| CN114848517A (en) | Moisturizing, oil-controlling, anti-inflammatory, bacteriostatic and acne-removing composition, acne-removing cosmetic containing composition and preparation method of acne-removing cosmetic | |
| KR20060020630A (en) | Topical treatment of sebum related skin conditions | |
| KR20080031156A (en) | Hair tonic | |
| JPH09241146A (en) | Skin external agent | |
| JPH09301880A (en) | Preparation for external use for skin | |
| CN115671022B (en) | Anti-aging microcapsule composition and preparation method and application thereof | |
| AU2011248152B2 (en) | Compositions comprising extracts of Southernwood and an amine compound | |
| KR100371028B1 (en) | Cosmetic composition containing Salvia militiorrhira Bge. extracts and polyethoxylated retinamide | |
| CN114159333B (en) | Myobase liquid and preparation method thereof | |
| JP3432175B2 (en) | Cell growth promotion cosmetics | |
| CN113425661B (en) | Plant composition with cleaning and repairing effects and application thereof | |
| JPS59216812A (en) | Hair restoring agent | |
| KR101154772B1 (en) | Cosmetic composition containing the zizyphus jujuba fruit extract and walnut extract for moisturizing effect on the skin | |
| JP3101090B2 (en) | External preparation for skin | |
| CN113499271A (en) | Anti-allergy compound and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |